2016 US lymphoid malignancy statistics by World Health Organization subtypes

Teras, Lauren R.; DeSantis, Carol; Cerhan, James R.; Morton, Lindsay M.; Jemal, Ahmedin; Flowers, Christopher R.

doi:10.3322/caac.21357

Cited by 871 publications

(709 citation statements)

References 62 publications

Supporting

Mentioning

610

Contrasting

Unclassified

Order By: Relevance

“…1 Despite its aggressive disease course,~50% to 70% of patients may be cured by current standard of care consisting of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. 2 Nevertheless, R-CHOP is found to be inadequate in 30% to 40% of patients.…”

Section: Introductionmentioning

confidence: 99%

Diffuse large B-cell lymphoma: R-CHOP failure—what to do?

2016

View full text Add to dashboard Cite

Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL),~30% to 50% of patients are not cured by this treatment, depending on disease stage or prognostic index. Among patients for whom R-CHOP therapy fails, 20% suffer from primary refractory disease (progress during or right after treatment) whereas 30% relapse after achieving complete remission (CR). Currently, there is no good definition enabling us to identify these 2 groups upon diagnosis. Most of the refractory patients exhibit double-hit lymphoma (MYC-BCL2 rearrangement) or double-protein-expression lymphoma (MYC-BCL2 hyperexpression) which have a more aggressive clinical picture. New strategies are currently being explored to obtain better CR rates and fewer relapses. Although young relapsing patients are treated with high-dose therapy followed by autologous transplant, there is an unmet need for better salvage regimens in this setting. To prevent relapse, maintenance therapy with immunomodulatory agents such as lenalidomide is currently undergoing investigation. New drugs will most likely be introduced over the next few years and will probably be different for relapsing and refractory patients. Learning Objectives• To be able to determine at diagnosis which DLBCL patients will likely experience treatment failure with R-CHOP • To understand the mechanisms that underlie resistance to standard treatments • To be able to assess the new proposed drugs, along with their efficacy for specific lymphoma populations such as those with double-hit lymphoma or double-protein-expression lymphoma • To learn more about potential solutions for refractory or relapsing patients

show abstract

Section: Introductionmentioning

confidence: 99%

Diffuse large B-cell lymphoma: R-CHOP failure—what to do?

2016

View full text Add to dashboard Cite

show abstract

“…About 4,292,000 new cases of cancer and 2,814,000 cancer-related deaths were estimated in China in 2015 [2]. It was reported that leukemia is the sixth leading cause of cancer death [3].…”

Section: Aimmentioning

confidence: 99%

“…About 4,292,000 new cases of cancer and 2,814,000 cancer-related deaths were estimated in China in 2015 [2]. It was reported that leukemia is the sixth leading cause of cancer death [3].Both genetic and environmental factors have been reported to cause of leukemia [4,5]. Combination of chemotherapy, radiation therapy and bone marrow transplant are involved in treatment of leukemia [6].…”

mentioning

confidence: 99%

The Mechanistic Antitumor Study of Myricanol 5-Fluorobenzyloxy Ether in Human Leukemic Cell Hl-60

Dai

Fan

Ren³

et al. 2017

Future Med. Chem.

View full text Add to dashboard Cite

Aim:The aim of the study was to explore the growth inhibitory effect of myricanol 5-fluorobenzyloxy ether (5FEM) and the underlying mechanism in human leukemic cells HL-60. Materials & methods: 5FEM was obtained by chemical modification of myricanol with fluorobenzyloxy ether at the OH(5) position. The cytotoxicity, cell apoptosis, cell cycle and the expression of key apoptosis-related genes in HL-60 were evaluated. Results & conclusion: 5FEM can significantly inhibited growth of HL-60 cells, increased the G2/M population and upregulated the expression of Bax, Fas, FasL, caspase-9 and p21 and downregulated that of Bcl-2 and survivin. The results enhance our understanding of 5FEM and aid the discovery of novel myricanol derivatives as potential antitumor agents. The incidence and mortality of cancer have been increasing in China [1]. About 4,292,000 new cases of cancer and 2,814,000 cancer-related deaths were estimated in China in 2015 [2]. It was reported that leukemia is the sixth leading cause of cancer death [3].Both genetic and environmental factors have been reported to cause of leukemia [4,5]. Combination of chemotherapy, radiation therapy and bone marrow transplant are involved in treatment of leukemia [6]. But these treatments have limitations because of a high probability of relapse and toxicity. Traditional Chinese medicine and natural plants have been used in the treatment of cancer for thousands of years in China. Owing to its minor side effects and good curative efficacy, the screening of anticancer drugs from traditional Chinese herbal medicine has increased considerably over the past few years [7,8].Myrica rubra (Lour.) Sieb. Et Zucc., a myricaceae Myrica plant, found in China and other Asian countries. Because of its biological properties, the bark of M. rubra is used in Chinese folk medicine [9][10][11]. Myricanol is a cyclic diarylheptanoid isolated from the bark of M. rubra. Diarylheptanoids exhibit various biological activities, including antitumor [12], antiviral [13], antioxidant [14] and anti-inflammatory [15] owing to its unique chemical structure. Our previous studies have shown that myricanol significantly inhibits the proliferation of human lung adenocarcinoma (A549), hepatoma (HepG2) and human promyelocytic leukemia (HL-60) cells. Further, it increased the caspase-3, caspase-9, Bax and p21 expression and decreased the expressions of Bcl-2 at the mRNA and protein levels [16]. Myricanol significantly induced tumor growth inhibitory effects on the xenografts of lung adenocarcinoma A549 by upregulating the expression of Bax and downregulating that of survivin, Bcl-2, VEGF and HIF-1α. The experimentation has indicated that the possible antitumor effects of myricanol are via the mitochondrial apoptosis pathway [17].In order to improve anticancer effect of myricanol, and to further explore the structure-activity relationship of myricanol and discover novel myricanol derivatives as antitumor agents, some novel myricanol derivatives, such as 5-fluorobenzyloxy ether (5FEM), myricanol 5-chlorobe...

show abstract

“…Lymphoid neoplasms are reported to be the fourth most common malignancy in the US and the sixth leading cause of cancer-related deaths [1]. Extra-nodal lymphomas are seen most commonly in the skin, followed by stomach, oropharynx, and small intestine.…”

Section: Introductionmentioning

confidence: 99%

“…The vast majority of gastrointestinal tract lymphomas are B-cell in origin and are found in the stomach, while only a small percentage are T-cell lymphomas and these are most commonly seen in the small bowel [2]. Enteropathy-associated T-cell lymphoma (EATL) is a rare entity with approximately 50 new cases reported in 2016 [1]. It is estimated that around 2–3% of patients with celiac disease (CD) develop an intestinal lymphoma, with 65% being of T-cell origin [3,4].…”

Section: Introductionmentioning

confidence: 99%

An unexpected deterrent in diagnosing refractory celiac disease and enteropathy-associated T-cell lymphoma: a gluten-free diet

Hussain

Hussain²,

Chatterjee

et al. 2018

Journal of Community Hospital Internal Medicine Perspectives

View full text Add to dashboard Cite

Enteropathy-associated T-cell lymphoma (EATL) is a rare disease found in the small bowel and is seen most commonly in patients with refractory celiac disease (RCD). We present a case of an elderly male with celiac disease (CD) diagnosed in childhood with months of abdominal pain and diarrhea despite attempting to avoid gluten in his diet. After persistent symptoms for months, the patient was admitted for an acute abdomen and was found to have small bowel perforation due to a jejunal mass that was diagnosed as an EATL. In 2–5% of adult onset CD, serious complications such as RCD or malignancy develop. The clinical course for EATL is aggressive and generally has a poor prognosis. This case highlights the importance of early clinical suspicion for a small bowel malignancy in patients with a long-standing history of CD and acute worsening of symptoms. Early workup and diagnosis is vital in improving morbidity and mortality in patients with EATL.

show abstract

2016 US lymphoid malignancy statistics by World Health Organization subtypes

Cited by 871 publications

References 62 publications

Diffuse large B-cell lymphoma: R-CHOP failure—what to do?

Diffuse large B-cell lymphoma: R-CHOP failure—what to do?

The Mechanistic Antitumor Study of Myricanol 5-Fluorobenzyloxy Ether in Human Leukemic Cell Hl-60

An unexpected deterrent in diagnosing refractory celiac disease and enteropathy-associated T-cell lymphoma: a gluten-free diet

Contact Info

Product

Resources

About